The neutrophil-to-lymphocyte ratio: A narrative review

S.S. Faria; P.C. Fernandes; M.J.B. Silva; V.C. Lima; W. Fontes; R. Freitas; A.K. Eterovic; P. Forget

doi:10.3332/ecancer.2016.702

The neutrophil-to-lymphocyte ratio: A narrative review

S.S. Faria, P.C. Fernandes, M.J.B. Silva, V.C. Lima, W. Fontes, R. Freitas, A.K. Eterovic, P. Forget (Corresponding Author)

Research output: Contribution to journal › Article

68 Citations (Scopus)

Abstract

Cellular-mediated inflammatory response, lymphocytes, neutrophils, and monocytes are increasingly being recognised as having an important role in tumorigenesis and carcinogenesis. In this context, studies have suggested that the neutrophil-to-lymphocyte ratio (NLR) can be used as an independent prognostic factor in a variety of cancers. Particularly in breast cancer, several studies have shown that a high NLR is associated with shorter survival. Because the NLR can be easily determined from the full blood count, it could potentially provide a simple and inexpensive test cancer prognosis. This review addresses the possibilities and limitations of using the NLR as a clinical tool for risk stratification helpful for individual treatment of breast cancer patients. The potential underlying phenomena and some perspectives are discussed.

Original language	English
Article number	702
Journal	ecancermedicalscience
Volume	10
DOIs	https://doi.org/10.3332/ecancer.2016.702
Publication status	Published - 12 Dec 2016

Keywords

breast cancer
inflammation
neutrophil-to-lymphocyte ratio
prognosis

Access to Document

10.3332/ecancer.2016.702Licence: CC BY

ecancermedicalscience-2016-article-702
Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Final published version, 331 KBLicence: CC BY

http://www.scopus.com/inward/record.url?eid=2-s2.0-85009250645&partnerID=MN8TOARS

Fingerprint Dive into the research topics of 'The neutrophil-to-lymphocyte ratio: A narrative review'. Together they form a unique fingerprint.

Cite this

Faria, S. S., Fernandes, P. C., Silva, M. J. B., Lima, V. C., Fontes, W., Freitas, R., Eterovic, A. K., & Forget, P. (2016). The neutrophil-to-lymphocyte ratio: A narrative review. ecancermedicalscience, 10, [702]. https://doi.org/10.3332/ecancer.2016.702

@article{edd692c8255b4ca3b288085cc18b7a16,

title = "The neutrophil-to-lymphocyte ratio: A narrative review",

abstract = "Cellular-mediated inflammatory response, lymphocytes, neutrophils, and monocytes are increasingly being recognised as having an important role in tumorigenesis and carcinogenesis. In this context, studies have suggested that the neutrophil-to-lymphocyte ratio (NLR) can be used as an independent prognostic factor in a variety of cancers. Particularly in breast cancer, several studies have shown that a high NLR is associated with shorter survival. Because the NLR can be easily determined from the full blood count, it could potentially provide a simple and inexpensive test cancer prognosis. This review addresses the possibilities and limitations of using the NLR as a clinical tool for risk stratification helpful for individual treatment of breast cancer patients. The potential underlying phenomena and some perspectives are discussed.",

keywords = "breast cancer, inflammation, neutrophil-to-lymphocyte ratio, prognosis",

author = "S.S. Faria and P.C. Fernandes and M.J.B. Silva and V.C. Lima and W. Fontes and R. Freitas and A.K. Eterovic and P. Forget",

year = "2016",

month = dec,

day = "12",

doi = "10.3332/ecancer.2016.702",

language = "English",

volume = "10",

journal = "ecancermedicalscience",

issn = "1754-6605",

publisher = "Cancer Intellilgence",

}

TY - JOUR

T1 - The neutrophil-to-lymphocyte ratio

T2 - A narrative review

AU - Faria, S.S.

AU - Fernandes, P.C.

AU - Silva, M.J.B.

AU - Lima, V.C.

AU - Fontes, W.

AU - Freitas, R.

AU - Eterovic, A.K.

AU - Forget, P.

PY - 2016/12/12

Y1 - 2016/12/12

N2 - Cellular-mediated inflammatory response, lymphocytes, neutrophils, and monocytes are increasingly being recognised as having an important role in tumorigenesis and carcinogenesis. In this context, studies have suggested that the neutrophil-to-lymphocyte ratio (NLR) can be used as an independent prognostic factor in a variety of cancers. Particularly in breast cancer, several studies have shown that a high NLR is associated with shorter survival. Because the NLR can be easily determined from the full blood count, it could potentially provide a simple and inexpensive test cancer prognosis. This review addresses the possibilities and limitations of using the NLR as a clinical tool for risk stratification helpful for individual treatment of breast cancer patients. The potential underlying phenomena and some perspectives are discussed.

AB - Cellular-mediated inflammatory response, lymphocytes, neutrophils, and monocytes are increasingly being recognised as having an important role in tumorigenesis and carcinogenesis. In this context, studies have suggested that the neutrophil-to-lymphocyte ratio (NLR) can be used as an independent prognostic factor in a variety of cancers. Particularly in breast cancer, several studies have shown that a high NLR is associated with shorter survival. Because the NLR can be easily determined from the full blood count, it could potentially provide a simple and inexpensive test cancer prognosis. This review addresses the possibilities and limitations of using the NLR as a clinical tool for risk stratification helpful for individual treatment of breast cancer patients. The potential underlying phenomena and some perspectives are discussed.

KW - breast cancer

KW - inflammation

KW - neutrophil-to-lymphocyte ratio

KW - prognosis

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-85009250645&partnerID=MN8TOARS

U2 - 10.3332/ecancer.2016.702

DO - 10.3332/ecancer.2016.702

M3 - Article

VL - 10

JO - ecancermedicalscience

JF - ecancermedicalscience

SN - 1754-6605

M1 - 702

ER -